CVS Health Corporation $CVS Holdings Raised by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. lifted its stake in CVS Health Corporation (NYSE:CVS) by 10.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 229,362 shares of the pharmacy operator’s stock after buying an additional 20,884 shares during the quarter. Rakuten Investment Management Inc.’s holdings in CVS Health were worth $19,977,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kilter Group LLC bought a new position in CVS Health during the second quarter valued at $27,000. Beaird Harris Wealth Management LLC grew its stake in shares of CVS Health by 201.0% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 195 shares in the last quarter. J.Safra Asset Management Corp bought a new stake in shares of CVS Health in the 2nd quarter worth about $30,000. Timbuktu Capital Management LLC bought a new stake in shares of CVS Health in the 2nd quarter worth about $31,000. Finally, Dunhill Financial LLC purchased a new stake in shares of CVS Health during the 2nd quarter valued at about $32,000. Institutional investors own 80.66% of the company’s stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported Q3 adjusted earnings of $2.09 per share, above the $1.65 consensus estimate, while revenue rose 5.4% year over year to $108.4 billion. Management raised its 2026 adjusted EPS outlook to at least $8.20 from a prior range of $7.90–$8.10. CVS Q3 results and guidance
• Neutral Sentiment: The company plans to separate its retail pharmacy business from its health benefits, pharmacy-benefit and care operations, creating two publicly traded companies by the first half of 2028. CVS says the businesses could gain focus and strategic flexibility, though the separation is still more than a year away. CVS breakup plan
• Negative Sentiment: The breakup announcement appears to be the main overhang: investors are reacting warily to CVS reversing its vertically integrated strategy, including the Aetna combination, despite the earnings beat. The scale and complexity of unwinding the businesses may be fueling uncertainty around execution and the value of the new structure. Market reaction to CVS split plan

Wall Street Analysts Forecast Growth

Several research firms recently commented on CVS. JPMorgan Chase & Co. lifted their price target on CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Wells Fargo & Company upped their price objective on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Barclays upped their price objective on CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Wall Street Zen lowered CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $103.00 target price on shares of CVS Health in a report on Wednesday. Twenty-two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $109.46.

CVS Health Stock Down 12.6%

NYSE:CVS opened at $79.90 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The company has a 50-day moving average of $90.82 and a 200 day moving average of $88.86. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The firm has a market cap of $102.19 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.65 by $0.44. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $108.40 billion during the quarter, compared to the consensus estimate of $104.72 billion. During the same period in the previous year, the company posted $1.60 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. As a group, research analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd were given a dividend of $0.6650 per share. This represents a $2.66 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.